Perrone, E., Manara, P., Lopez, S., Bellone, S., Bonazzoli, E., Manzano, A., . . . Santin, A. D. (2020). Sacituzumab govitecan, an antibody‐drug conjugate targeting trophoblast cell‐surface antigen 2, shows cytotoxic activity against poorly differentiated endometrial adenocarcinomas in vitro and in vivo. Mol Oncol.
Čikaški stil citiranjaPerrone, Emanuele, et al. "Sacituzumab Govitecan, an Antibody‐drug Conjugate Targeting Trophoblast Cell‐surface Antigen 2, Shows Cytotoxic Activity against Poorly Differentiated Endometrial Adenocarcinomas In vitro and In vivo." Mol Oncol 2020.
MLA način citiranjaPerrone, Emanuele, et al. "Sacituzumab Govitecan, an Antibody‐drug Conjugate Targeting Trophoblast Cell‐surface Antigen 2, Shows Cytotoxic Activity against Poorly Differentiated Endometrial Adenocarcinomas In vitro and In vivo." Mol Oncol 2020.